CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 6.4: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.79%Below 5Y avg (1.13%)
Annual Rate
CNY 0.05Paid annual
Payout Ratio
757.6%High
Last Ex-Dividend
Jun 18, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.09BCNY458.75M · vs all stocks (USD)
Revenue (TTM)
842.50MCNY125.13M · vs all stocks (USD)
Profit Margin
-0.97%vs Biotechnology peers
Beta
0.2870xvs all stocks
52-Week Change
-19.57%vs all stocks
Market Capitalization
3.09BCNY458.75M · vs all stocks (USD)
Enterprise Value
2.57BCNY382.10M · vs all stocks (USD)
Forward P/E
28.82xvs Biotechnology peers
Price to Sales (TTM)
3.70xvs Biotechnology peers
Price to Book (MRQ)
1.19xvs Biotechnology peers
Enterprise to Revenue
3.05xvs Biotechnology peers
Enterprise to EBITDA
21.19xvs Biotechnology peers
Gross Margin
49.66%vs Biotechnology peers
Profit Margin
-0.97%vs Biotechnology peers
Operating Margin
7.48%vs Biotechnology peers
Return on Assets (TTM)
-0.21%vs Biotechnology peers
Return on Equity (TTM)
-0.24%vs Biotechnology peers
Revenue (TTM)
842.50MCNY125.13M · vs all stocks (USD)
Revenue per Share (TTM)
1.72CNYUpdated Aug 19, 2026Quarterly Revenue Growth
5.10%vs Biotechnology peers
Gross Profit (TTM)
376.31MCNY55.89M · vs all stocks (USD)
EBITDA (TTM)
130.61MCNY19.40M · vs all stocks (USD)
Net Income (TTM)
-8.16MCNY-1.21M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
238.50%vs Biotechnology peers
Operating Cash Flow (TTM)
157.73MCNY23.43M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-113.14MCNY-16.80M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0500CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.79%vs all stocks
5-Year Average Dividend Yield
1.13%vs all stocks
Payout Ratio
757.58%vs Biotechnology peers
Minority Interest (Equity)
43.66MCNYFY2025 · Dec 31, 2025Revenue
832.26MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
454.22MCNYFY2025 · Dec 31, 2025Gross Profit
378.04MCNYFY2025 · Dec 31, 2025Operating Income
122.71KCNY18.23K · vs all stocks (USD)
Pre-tax Income
-16.43MCNYFY2025 · Dec 31, 2025Income Tax Expense
2.11MCNYFY2025 · Dec 31, 2025Net Income
-18.54MCNYFY2025 · Dec 31, 2025EBIT
-15.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
130.61MCNYFY2025 · Dec 31, 2025Research & Development
104.95MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
181.23MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.05MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
12.34MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
730.56KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0403CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0403CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
490.81MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
490.81MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-18.54MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.24MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-41.32MCNYFY2025 · Dec 31, 2025Free Cash Flow
-318.43MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
254.87MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-18.54MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.63MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.75MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-23.67MCNYFY2025 · Dec 31, 2025Capital Expenditures
-277.11MCNYFY2025 · Dec 31, 2025Purchase of Investments
-737.39MCNYFY2025 · Dec 31, 2025Sale of Investments
865.82MCNYFY2025 · Dec 31, 2025Other Investing Activity
25.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-123.68MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
99.85MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-73.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-49.10MCNYFY2025 · Dec 31, 2025Other Financing Charges
5.49MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-16.76MCNYFY2025 · Dec 31, 2025Shares Outstanding
491.06MSharesUpdated Aug 19, 2026Float Shares
311.20MSharesUpdated Aug 19, 2026% Held by Insiders
38.51%vs all stocks
% Held by Institutions
2.39%vs all stocks
Total Cash (MRQ)
536.02MCNY79.61M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.12CNYUpdated Aug 19, 2026Total Debt (MRQ)
18.20MCNY2.70M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0070xvs Biotechnology peers
Current Ratio (MRQ)
4.91xvs Biotechnology peers
Book Value per Share (MRQ)
5.34CNYUpdated Aug 19, 2026Total Assets
2.92BCNY434.41M · vs all stocks (USD)
Total Current Assets
1.11BCNYFY2025 · Dec 31, 2025Total Liabilities
331.81MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.82BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
52.40MCNYFY2025 · Dec 31, 2025Total Current Liabilities
279.41MCNYFY2025 · Dec 31, 2025Cash
411.28MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
415.75MCNYFY2025 · Dec 31, 2025Other Short-term Investments
198.72MCNYFY2025 · Dec 31, 2025Accounts Receivable
199.34MCNYFY2025 · Dec 31, 2025Inventory
206.55MCNYFY2025 · Dec 31, 2025Accounts Payable
129.98MCNYFY2025 · Dec 31, 2025Short-term Debt
62.12MCNYFY2025 · Dec 31, 2025Other Current Liabilities
15.84MCNYFY2025 · Dec 31, 2025Common Stock (Book)
491.06MCNYFY2025 · Dec 31, 2025Retained Earnings
434.47MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.59BCNY385.13M · vs all stocks (USD)
Treasury Stock
100.11MCNYFY2025 · Dec 31, 202552-Week Low
5.36CNYUpdated Aug 19, 202652-Week High
7.88CNYUpdated Aug 19, 202652-Week Change
-19.57%vs all stocks
Beta
0.2870xvs all stocks
50-Day MA
5.84CNYUpdated Aug 19, 2026200-Day MA
6.56CNYUpdated Aug 19, 2026Avg 10-Day Volume
7.33MSharesUpdated Aug 19, 2026Avg 30-Day Volume
7.90MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.0200CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.50Profit Margin: -0.01
Financial Health
Altman Z-Score 6.4: safe zoneNotable
Altman Z-Score: 6.40
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Baolingbao Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Qingdao Vland Biotech Inc.
Tier 1ProductionApproval-Gated PipelineFlow